Numab AG bags CHF70m in licencing dealSwiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc. more ➔
Biogen bags UK company Nightstar for US$877mBiogen has strengthened its portfolio with Nightstar Therapeutics, a British gene therapy specialist for rare inherited eye disorders. more ➔
EMA approves eight meds for marketThe EMA’s human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authori … more ➔
Genfit set to raise $100m in Nasdaq IPOFrench Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US. more ➔
Targeting NFkappaB protects tendons from injuryResearchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation. more ➔
Anaveon bags CHF35m series A financingUniversity Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist. more ➔
AMR network CARB-X expands reachThe global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR). more ➔
Roche swallows Spark Therapeutics in $4.3bn dealSwiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn. more ➔
How salt triggers allergySodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells. more ➔
Calypso Biotech cash in €20M Series A financingDutch autoimmunity specialist Calypso Biotech BV has raised €20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation … more ➔
